Yuhan said on the 6th that last year's out-of-hospital prescriptions for the dyslipidemia treatment "Rosuvamibe" exceeded 100 billion won.
According to out-of-hospital prescription sales data from the pharmaceutical market research firm UbIST, Rosuvamibe's prescriptions last year totaled 102.2 billion won. It came about 10 years after its 2016 launch.
Rosuvamibe is a combination drug that pairs ezetimibe and rosuvastatin. The company said that in clinical trials of patients aged 70 or older with atherosclerotic cardiovascular disease (ASCVD), compared with high-intensity rosuvastatin monotherapy, the incidence of statin-related muscle adverse reactions and new-onset diabetes was significantly lower, while the LDL cholesterol reduction effect was similar.